Skip to main content

Web Exclusives

Drug Resistance

Oral Toxicities Associated with Cancer Therapies: What’s Old Is New Again

Meg Barbor, MPH

TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition

FDA Updates

Lenvima Now Approved for Unresectable Hepatocellular Carcinoma

Immunotherapy

Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Skin Cancer

Immunotherapy

CAR T-Cell Therapy Yields Impressive Responses in Aggressive Blood Cancer

Breast Cancer

Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer

Immunotherapy

Immunotherapy Combinations “Raising the Bar”

Screening

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

Breast Cancer

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

Immunotherapy, Multiple Myeloma

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Page 28 of 43
Results 271 - 280 of 430